News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,573 Results
Type
Article (8023)
Company Profile (140)
Press Release (476313)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166743)
Career Advice (304)
Deals (25740)
Drug Delivery (7)
Drug Development (52876)
Employer Resources (14)
FDA (9760)
Job Trends (8572)
News (238201)
Policy (17903)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (487)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33162)
ALS (104)
Alzheimer's disease (974)
Antibody-drug conjugate (ADC) (262)
Approvals (10370)
Artificial intelligence (319)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6963)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (507)
Cancer (3628)
Cardiovascular disease (217)
Career advice (246)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (476)
Cervical cancer (34)
Clinical research (47852)
Collaboration (1239)
Commercialization (3)
Compensation (1451)
Complete response letters (34)
COVID-19 (756)
CRISPR (63)
C-suite (737)
Cystic fibrosis (85)
Data (5627)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4178)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73688)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87598)
Executive appointments (698)
FDA (12370)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (911)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (289)
Government (953)
Grass and pollen (2)
Guidances (281)
Healthcare (9328)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (156)
Infectious disease (944)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (42)
IPO (12390)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5209)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (505)
Lymphoma (249)
Machine learning (27)
Management (3)
Manufacturing (528)
Marketing (8)
MASH (118)
Medical device (8652)
Medtech (8792)
Mergers & acquisitions (14379)
Metabolic disorders (704)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1818)
NextGen: Class of 2026 (3154)
Non-profit (846)
Obesity (223)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (472)
Patient recruitment (502)
Peanut (31)
People (41229)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15459)
Phase 2 (21370)
Phase 3 (14393)
Pipeline (7248)
Policy (18)
Postmarket research (1572)
Preclinical (6537)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3021)
Recruiting (6)
Regulatory (14806)
Reports (20)
Research institute (583)
Resumes & cover letters (46)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (121)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
Vaccines (318)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (22)
Last 7 days (461)
Last 30 days (1599)
Last 365 days (19047)
2026 (12098)
2025 (19251)
2024 (22995)
2023 (26539)
2022 (34596)
2021 (37176)
2020 (33470)
2019 (23257)
2018 (17471)
2017 (18766)
2016 (17920)
2015 (24263)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20441)
2010 (20332)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (300)
Arkansas (11)
Asia (17880)
Australia (2097)
California (11909)
Canada (3127)
China (517)
Colorado (482)
Connecticut (408)
Delaware (207)
Europe (24618)
Florida (1782)
Georgia (376)
Hawaii (3)
Idaho (46)
Illinois (695)
India (48)
Indiana (314)
Iowa (14)
Japan (398)
Kansas (101)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1194)
Massachusetts (7828)
Michigan (307)
Minnesota (559)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2613)
New Mexico (12)
New York (2811)
North Carolina (1267)
North Dakota (4)
Northern California (5962)
Ohio (276)
Oklahoma (14)
Oregon (16)
Pennsylvania (2245)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4945)
Tennessee (119)
Texas (1927)
United States (38694)
Utah (358)
Vermont (1)
Virginia (152)
Washington D.C. (38)
Washington State (923)
West Virginia (1)
Wisconsin (73)
484,573 Results for "tricida inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Tricida Provides Strategic Update
Tricida, Inc., announced that the Board of Directors has authorized Tricida to initiate a review of strategic alternatives to maximize stakeholder value.
November 2, 2022
·
3 min read
Business
Tricida Announces Third Quarter 2022 Financial Results
Tricida, Inc. announced financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives.
November 14, 2022
·
9 min read
Business
Tricida Announces Second Quarter 2022 Financial Results
Tricida, Inc. announced financial results for the three and six months ended June 30, 2022 and provided an update on key initiatives.
August 8, 2022
·
10 min read
Biotech Bay
Tricida Announces $125 Million Debt Facility with Hercules Capital
Tricida, Inc. announced that it has entered into a debt facility with Hercules Capital, Inc., a leader in customizing debt financing for companies in the life sciences and technology-related markets.
October 19, 2022
·
4 min read
Biotech Bay
Tricida to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Tricida, Inc. announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference. Tricida will provide a company overview, business update and progress on the company’s key initiatives.
September 6, 2022
·
1 min read
Drug Development
Reeling from CKD Flop, Tricida Downsizes by Nearly 60%
Tricida, Inc. is reducing its headcount by around 57% to improve its financial standing after its lead candidate failed in a Phase III trial, the company revealed in its third-quarter financial results.
November 16, 2022
·
2 min read
·
Tristan Manalac
Business
Tricida Announces First Quarter 2022 Financial Results
Tricida, Inc. announced financial results for the three months ended March 31, 2022 and provided an update on key initiatives.
May 10, 2022
·
9 min read
Drug Development
Tricida Stocks Plummet Following Trial Failure in Kidney Disease
Top-line data from Tricida’s VALOR-CKD trial showed veverimer failed to meet its primary endpoint and does not slow progression in patients with metabolic acidosis and CKD.
October 24, 2022
·
2 min read
·
Tristan Manalac
Drug Development
Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer
Tricida, Inc. (NASDAQ: TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer’s ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD).
October 24, 2022
·
9 min read
Business
Tricida Announces Fourth Quarter and Full Year 2021 Financial Results
Tricida, Inc. announced financial results for the three months and year ended December 31, 2021 and provided an update on key initiatives.
March 29, 2022
·
11 min read
1 of 48,458
Next
